News for Alterity Therapeutics Limited (ATHE)

MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, ATHE) (”œAlterity” or ”œthe Company”), a bi

”“ Clinically Meaningful Efficacy Observed on Multiple Assessments ”“ ”“ Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Region

Alterity Therapeutics Limited (ATHE), Thursday announced the data from ATH434 Phase 2 trial in patients with Multiple System Atrophy or MSA. The findings showed clinically meaningful efficacy across multiple measures.

**media[584926]**

”“ Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders ”“ ”“ Capital raising was strongly supported by domestic and intern

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fel...

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.26% to 44,829.59 while the NASDAQ gain...

**media[528039]**

**media[523364]**

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in

**media[510655]**

”“ ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders ”“ ”“ Topline Data Expected in Early 2025 ”“

Opthea adds Kathy Connell to Board of Directors

Alterity Therapeutics to join Maxim Healthcare Summit

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Alterity Therapeutics Receives a $3.9 million Research & Development Tax Incentive Refund March 26, 2024March 26, 2024 Alterity Therapeutics ...

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a stro